Literature DB >> 11694325

Acetylcholine receptor-reactive antibody induces nitric oxide production by a rat skeletal muscle cell line: influence of cytokine environment.

Y R Garcia1, J J May, A M Green, K A Krolick.   

Abstract

The monoclonal Lewis rat skeletal muscle cell line, LE1, responded to the acetylcholine receptor (AChR)-reactive antibody mAb35 by up-regulating levels of mRNA for inducible nitric oxide synthase (iNOS/NOS-II), followed by levels of NO. Interferon-gamma (IFN-gamma) and interleukin-1 (IL-1) were also each capable of inducing iNOS message, and synergistically with mAb35. Finally, myocyte-derived NO was implicated as a possible source of immunomodulation in experimental autoimmune myasthenia gravis (EAMG), as shown by the ability of the culture fluids from IFN-gamma-activated LE1 cells to inhibit the proliferation of AChR-reactive T cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11694325     DOI: 10.1016/s0165-5728(01)00414-3

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  4 in total

1.  Bacterial colonization and the expression of inducible nitric oxide synthase in murine wounds.

Authors:  Eric Mahoney; Jonathan Reichner; Leslie Robinson Bostom; Balduino Mastrofrancesco; William Henry; Jorge Albina
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

3.  IL-4 receptor as a bridge between the immune system and muscle in experimental myasthenia gravis I: up-regulation of muscle IL-15 by IL-4.

Authors:  Sabrina Shandley; Sonia Martinez; Keith Krolick
Journal:  Clin Immunol       Date:  2009-04-22       Impact factor: 3.969

Review 4.  The Muscle Is Not a Passive Target in Myasthenia Gravis.

Authors:  Jean-Thomas Vilquin; Alexandra Clarissa Bayer; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Front Neurol       Date:  2019-12-19       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.